SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

INCB161734

INCY·INCYTE CORP
MIXED
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If Phase 3 DAWN-303 succeeds, earliest potential regulatory submission would be around 2029-2030, given topline data expected in 2028.
Why 4/10
No hard binary catalyst is scheduled within the next ~12 months. The Phase 3 DAWN-303 topline readout is expected in 2028, and a Phase 3 adjuvant PDAC study is planned for 2027 (trial start, not data). Incyte is a multi-product company, so this single asset does not define the stock. Impact score reflects a mid-to-late stage investigational drug with impressive early data but no near-term approval or pivotal readout catalyst.
Actionable Insight MIXED

The ESMO 2026 Phase 1 data just landed (Oct 26) so this is the immediate catalyst cleared. The next major binary event is DAWN-303 Phase 3 topline data, expected no earlier than 2028 -- years out. In the nearer term, watch for Phase 3 adjuvant PDAC trial initiation (plans for 2027), the Genmab collaboration Phase 1/2 CRC study starting enrollment, and any competitive updates from Revolution Medicines' zoldonrasib program, which Incyte sees as its primary rival in the KRAS G12D space.

Price Chart

Loading chart...

Executive Summary

INCB161734 (zecdarasib) is Incyte's investigational oral KRAS G12D inhibitor, a targeted therapy for KRAS G12D-mutated cancers -- most notably pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). On October 26, 2026 at ESMO, Incyte reported striking Phase 1 data: a 89% confirmed objective response rate and 90% six-month landmark progression-free survival when combined with chemo in first-line metastatic PDAC. A global Phase 3 trial (DAWN-303) in first-line PDAC is underway with topline data expected in 2028. The drug also showed a 36% response rate in later-line CRC with cetuximab, and a Phase 3 CRC study (DAWN-302) is being planned. Incyte is a diversified biopharma with approved products (Jakafi, Opzelura), so INCB161734 is one pipeline asset among several, but a potentially high-value one given the large addressable PDAC market.

How It Works

INCB161734 is a daily pill that targets a specific mutated form of a protein called KRAS (the G12D mutation). About 40% of pancreatic cancers and 15% of colorectal cancers carry this mutation, which acts as an "always-on" growth switch for cancer cells. The drug binds to the mutant KRAS protein and turns it off, blocking the cancer's growth signals. It is highly selective for the mutated form over normal KRAS (more than 80-fold selectivity) and is designed to work in both the active and inactive states of the protein.

Trial Status

Phase 1 monotherapy and combination dose-escalation/expansion data presented at ESMO 2026 (Oct 26). The Phase 3 DAWN-303 trial (NCT07522073) is actively recruiting: a randomized, double-blind study of chemotherapy with or without INCB161734 in previously untreated KRAS G12D-mutated metastatic PDAC. A Phase 3 study in adjuvant PDAC is planned for 2027. A Phase 3 CRC study (DAWN-302) is being planned. A Phase 1/2 collaboration with Genmab evaluating INCB161734 + petosemtamab + chemo in first-line KRAS G12D-mutated mCRC was announced Oct 24, 2026.

The Two-Sided Case

▲ Bull Case5
Phase 1 data (ESMO 2026) showed a 89% confirmed objective response rate and 90% six-month landmark PFS when combined with mFOLFIRINOX in first-line metastatic PDAC, with a 100% disease control rate -- a standout result in a historically difficult-to-treat cancer (source: Investor press release Oct 26, 2026).
KRAS G12D is the most common KRAS mutation in pancreatic cancer (~40% of cases) and also prevalent in CRC (~15%), giving INCB161734 a large addressable patient population with significant unmet need (source: Annals of Oncology abstract).
Incyte is executing an aggressive clinical strategy with simultaneous Phase 3 (DAWN-303), planned adjuvant PDAC Phase 3, planned CRC Phase 3 (DAWN-302), and a Genmab collaboration for first-line CRC -- expanding the drug's potential across multiple indications (source: Incyte ESMO press release).
Analyst consensus on Incyte as of Oct 2026 shows 18 Buy/Strong Buy ratings with a mean price target of ~$129.54, implying roughly 11% upside from the $116.32 price.
Major institutional holders include Baker Bros. ($3.5B position), BlackRock, Dodge & Cox, and Vanguard, signaling strong institutional confidence in Incyte.
▼ Bear Case5
Competition from Revolution Medicines' zoldonrasib (RMC-9805) is intense; zoldonrasib has already earned FDA Breakthrough Therapy designation for KRAS G12D NSCLC and is also being studied in pancreatic cancer -- Incyte sees itself as 'neck and neck' with RevMed in this space (source: FierceBiotech Oct 26, 2026).
The Phase 1 data, while impressive, comes from a small, single-arm cohort (n=27 for the mFOLFIRINOX cohort) and median PFS/mature overall survival data are not yet available; large randomized Phase 3 data are years away (2028), leaving significant clinical and regulatory risk (source: STAT News Oct 26, 2026).
Incyte's broader pipeline carries its own execution risk; the company reported Q3 2026 EPS of -$3.60, below estimates, highlighting near-term financial headwinds despite approved product revenue.
Phase 3 DAWN-303 trials in pancreatic cancer are notoriously difficult -- many targeted agents have failed in the Phase 3 setting despite promising Phase 1/2 data, including in KRAS-mutant populations. The risk of failure is meaningful.
The stock has mixed institutional signals: while Baker Bros. is heavily long, multiple large holders (LA Capital Mgmt trimmed -73%, Price T Rowe trimmed -45.5%, UBS trimmed -32.5%) reduced positions in Q2 2026.

Upcoming Catalysts

  • Phase 3 DAWN-303 topline data in first-line metastatic PDAC (expected 2028)
  • Initiation of Phase 3 adjuvant PDAC study (planned 2027)
  • Phase 3 CRC DAWN-302 study initiation in previously treated mCRC
  • Phase 1/2 Genmab collaboration study enrollment data (INCB161734 + petosemtamab + chemo in first-line KRAS G12D mCRC)
  • Competitive updates from Revolution Medicines' zoldonrasib program in PDAC and NSCLC

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INCYTE CORP 8-K INCY ·Originating report

Sources · 12

Hover a chip for the title
1 investor.incyte.com2 investor.incyte.com3 statnews.com4 biospace.com5 fiercebiotech.com6 marketscreener.com7 onclive.com8 ascopubs.org9 drughunter.com10 cancer.gov11 dana-farber.org12 clinicaltrials.gov